In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa

被引：12
作者：
Piccoli, L
Guerrini, M
Felici, A
Marchetti, F
机构：
[1] GlaxoSmithKline SpA, Dept Med, I-37135 Verona, Italy
[2] GlaxoSmithKline SpA, Med Res Ctr, I-37135 Verona, Italy
来源：
JOURNAL OF CHEMOTHERAPY | 2005年 / 17卷 / 04期
关键词：
experimental infections; checkerboard testing; levofloxacin; ceftazidime; amikacin; Pseudomonas aeruginosa;
D O I：
10.1179/joc.2005.17.4.355
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The aim of the present study was to explore the antibacterial activity of the levofloxacin (LVX) and ceftazidime (CAZ) combination compared with the amikacin (AMK)/CAZ combination against Pseudomonas aeruginosa. Minimum inhibitory concentrations (MICs) were determined according to NCCLS. FIC indices (FI) were calculated by the checkerboard technique. CAZ combined with LVX or AMK yielded FIs indicating synergism (FI < 0.5) for 71/102 (69.6%) and 81/102 (79.4%)(p=0.108), indifference (FI > 0.5-4) for 24/102 (23.5%) and 12/102 (11.7%) (p=0.027), and antagonism (FI > 4) for 7/102 (6.8%) and 9/102 (8.8%) (p=0.602) strains, respectively. In vivo, CAZ/LVX was as bactericidal as CAZ/AMK combination. Our results support the potential role of LVX as an alternative to AMK in the combination therapy with CAZ in the treatment of P. aeruginosa severe infections. Anyway, further investigations and clinical trials are awaited until any definitive conclusions can be drawn.
引用
收藏
页码：355 / 360
页数：6
相关论文
共 31 条
[1]   Guidelines for the management, of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia [J].
不详 .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (04) :388-416
[2]   Antimicrobial susceptibility profiles of Pseudomonas aeruginosa and Staphylococcus aureus isolated in Italy from patients with hospital-acquired infections [J].
Blandino, G ;
Marchese, A ;
Ardito, F ;
Fadda, G ;
Fontana, R ;
Lo Cascio, G ;
Marchetti, F ;
Schito, GC ;
Nicoletti, G .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (05) :515-518
[3]   In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams [J].
Bonfiglio, G ;
Marchetti, F .
CHEMOTHERAPY, 2000, 46 (04) :229-234
[4]   Antibiotic resistance in Pseudomonas aeruginosa:: an Italian survey [J].
Bonfiglio, G ;
Carciotto, V ;
Russo, G ;
Stefani, S ;
Schito, GC ;
Debbia, E ;
Nicoletti, G .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (02) :307-310
[5]   ROLES OF RIBOSOMAL-BINDING, MEMBRANE-POTENTIAL, AND ELECTRON-TRANSPORT IN BACTERIAL UPTAKE OF STREPTOMYCIN AND GENTAMICIN [J].
BRYAN, LE ;
KWAN, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 23 (06) :835-845
[6]   Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa [J].
Burgess, DS ;
Nathisuwan, S .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 44 (01) :35-41
[7]   Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa [J].
Cappelletty, DM ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :677-683
[8]  
CRAIG W, 2001, PHARMACOTHERAP 3 S11, V21, pS337
[9]   Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp. [J].
Drago, L ;
De Vecchi, E ;
Nicola, L ;
Colombo, A ;
Guerra, A ;
Gismondo, MR .
CHEMOTHERAPY, 2004, 50 (04) :202-210
[10]  
Eliopolous GM., 1996, Antibiotics in laboratory medicine, P330
1234